Despite $5B sales for Keytruda, Merck hits two PhIII snags as it continues to build its multibillion-dollar drug
Continuing on its quest to grow Keytruda’s blockbuster status ahead of a 2028 patent cliff, Merck reported today that Keytruda has missed in two indications — as a first-line therapy in combination with Eisai’s Lenvima for liver cancer, and also as a later-line treatment for metastatic prostate cancer.
In the first case, when Merck and Eisai compared Keytruda plus Lenvima to Lenvima alone for liver cancer that can’t be removed by surgery, the combo therapy didn’t significantly change either overall survival or progression-free survival.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.